HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications

scientific article

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.DRUP.2004.03.003
P698PubMed publication ID15158765

P2093author name stringDaria J Hazuda
Michael D Miller
P433issue2
P304page(s)89-95
P577publication date2004-04-01
P1433published inDrug Resistance UpdatesQ3040081
P1476titleHIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications
P478volume7

Reverse relations

cites work (P2860)
Q37153758Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
Q39698701An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor.
Q34332580Antiviral drugs specific for coronaviruses in preclinical development
Q34315133Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection
Q33943822Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection
Q36558109Current developments in HIV chemotherapy
Q36150601Emerging anti-HIV drugs
Q36237524Emerging drug targets for antiretroviral therapy
Q39389791Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
Q92081948Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
Q34725136Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms
Q44113439Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure
Q35741691The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages
Q40444598The virion-associated Gag-Pol is decreased in chimeric Moloney murine leukemia viruses in which the readthrough region is replaced by the frameshift region of the human immunodeficiency virus type 1.
Q37247695Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.

Search more.